New York Mets infielder Nick Madrigal dislocated his left shoulder in the first inning of the club's split-squad contest ...
2don MSN
New York Mets infielder Nick Madrigal dislocated his non-throwing shoulder in a spring training game against the Washington ...
2don MSN
New York Mets starter Sean Manaea is expected to begin the season on the injured list because of a right oblique strain.
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...
The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...
Zacks.com on MSN2h
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpMadrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken, ...
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback